352 Longitudinal Infusion of Insulin-Like Growth Factor-I and Igf-Binding Protein-3 Complex to Five Preterm Infants - Pharmacokinetics and Short Term Safety

Introduction In preterm infants, low levels of insulin like growth factor-I (IGF-I) and IGF binding protein 3 (IGFBP-3) are associated with impaired brain growth and retinopathy of prematurity (ROP). Treatment with IGF-I/IGFBP-3 may be beneficial for brain development and decrease the prevalence of...

Full description

Saved in:
Bibliographic Details
Published in:Archives of disease in childhood 2012-10, Vol.97 (Suppl 2), p.A103-A103
Main Authors: Ley, D, HansenPupp, I, Niklasson, A, Domellöf, M, Friberg, L, Borg, J, Löfquist, C, Hellgren, G, Smith, L, Hård, AL, Hellström, A
Format: Article
Language:English
Subjects:
Body Weight
Brain
Infants
Pharmacokinetics
Premature Infants
Young Children
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction In preterm infants, low levels of insulin like growth factor-I (IGF-I) and IGF binding protein 3 (IGFBP-3) are associated with impaired brain growth and retinopathy of prematurity (ROP). Treatment with IGF-I/IGFBP-3 may be beneficial for brain development and decrease the prevalence of ROP. Methods In a phase II pharmacokinetic and safety study, five infants (3 girls) with a median (range) gestational age (GA) of 26+6 (26+0 – 27+2) weeks and birth weight (BW) of 990 (900–1212) g received continuous intravenous infusion of rhIGF-I/rhIGFBP-3. Treatment was initiated during the first postnatal day and continued for a median (range) duration of 168 h (47–168) in doses between 21–111 µg/kg/24h. Results Treatment with rhIGF-I/rhIGFBP-3 was associated with higher serum IGF-I and IGFBP-3 concentrations (p
ISSN:0003-9888
1468-2044
DOI:10.1136/archdischild-2012-302724.0352